A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of ECC4703 as an Adjunct to Semaglutide in Adults With Obesity

Registration

Registration

NCT07505303

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Phase

PHASE2

Masking

TRIPLE

Status

ACTIVE_NOT_RECRUITING

Enrollment

151

Start

2026-03-23

Primary completion

2026-10-15

Lead sponsor

Eccogene

Conditions

Adult Obesity; Weight Management

Interventions

DRUG:ECC4703; DRUG:Placebo; DRUG:Semaglutide

Results posted

FALSE

Individual participant data sharing

NO

Registered primary outcomes

• Percentage Change in Body Weight from Baseline (Week 9) to Week 20 [Baseline (Week 9) to Week 20]
• Proportion of Participants Achieving ≥5% Reduction in Body Weight from Baseline (Week 9) to Week 20 [Baseline (Week 9) to Week 20]
• Absolute Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic Steatosis [Baseline (Week 9) to Week 20]
• Percentage Change in Liver Fat Content as Measured by MRI-PDFF in Participants With Hepatic Steatosis [Baseline (Week 9) to Week 20]
• Proportion of Participants With ≥30% Relative Reduction in Liver Fat Content as Measured by MRI-PDFF [Baseline (Week 9) to Week 20]